Spasticity and muscle overactivity as components of the upper motor Neuron Syndrome

DeLisa's Physical Medicine and Rehabilitation: Principles and Practice: Fifth Edition

Volumn 2-2, Issue , 2012, Pages 1319-1344

  Elovic, Elie P ^a,b   Eisenberg, Michal E ^c   Jasey, Neil N ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84973428355     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (342)

1. Gans BM, Glenn MB. Introduction. In: Glenn MB, Whyte J, eds. The Practical Management of Spasticity in Children and Adults.. Philadelphia, PA: Lea & Febiger; 1990:1-7.
2. Maynard FM, Karunas RS, Waring WP Epidemiology of spasticity following traumatic spinal cord injury. Arch Phys Med Rehabil.. 1990;71(8):566-569.
3. Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler.. 2004;10(5):589-595.
4. Sommerfeld DK, Eek EU, Svensson AK, et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke.. 2004;35(1):134-139.
5. Watkins CL, Leathley MJ, Gregson JM, et al. Prevalence of spasticity post stroke. Clin Rehabil.. 2002;16(5):515-522.
6. Sherrington CS. On plastic tonus and proprioceptive reflexes. Q J Exp Neurol.. 1909;2:109-156.
7. Henneman E. Skeletal muscle: the servant of the nervous system. In: Mountcastle VB, ed. Medical Physiology.. St. Louis, MO: Mosby; 1980:674-702.
8. Whitlock JA. Neurophysiology of spasticity. In: Glenn MB, Whyte J, eds. The Practical Management of Spasticity in Children and Adults.. Philadelphia, PA: Lea & Febiger; 1990:8-33.
9. AAPMR, ed. Spasticity Management in the Patient with Brain Injury.. Orlando, FL: American Academy of PM&R; 1995.
10. Katz R, Pierrot-Deseilligny E. Recurrent inhibition of alpha-motorneurons in patients with upper motor neuron lesions. Brain.. 1982;105(pt 1):103-124.
11. Moore JC. The Golgi tendon organ: a review and update. Am J Occup Ther.. 1984;38:227-236.
12. Hultborn H, Illert M, Santani I. Convergence on interneurons mediating the reciprocal Ia inhibition of motorneurons. Acta Physiol Scand.. 1976;96:193-201.
13. Brooks VB. The Neural Basis of Motor Control.. New York, NY: Oxford University Press; 1986.
14. Shefner JM, Berman SA, Sarkarati M, et al. Recurrent inhibition is increased in patients with spinal cord injury. Neurology.. 1992;42(11):2162-2168.
15. Rothwell JC, Thompson PD, Day BL, et al. Stimulation of the human motor cortex through the scalp. Exp Physiol.. 1991;76:159-200.
16. Turton A, Fraser C, Flament W, et al. Organization of cortico-motorneuronal projections from the primary motor cortex; evidence for task related function in monkey and in man. In: Thrilmann AF, Burke DJ, Rymer WZ, eds. Spasticity: Mechanisms and Management.. Berlin, Germany: Springer; 1993:8-24.
17. Brodal A. Neurological Anatomy in Relationship to Clinical Medicine.. New York, NY: Oxford University Press; 1981.
18. Magoun HW, Rhines R. An inhibitory mechanism in the bulbar reticular formation. J Neurophysiol.. 1946;9:165-171.
19. Dietz V, Berger W. Normal and impaired regulation of muscle stiffness in gait: a new hypothesis about muscle hypertonia. Exp Neurol.. 1983;79(3):680-687.
20. Nielsen JB, Crone C, Hultborn H. The spinal pathophysiology of spasticity-from a basic science point of view. Acta Physiol (Oxf).. 2007;189(2):171-180.
21. Hagbarth KE. Exteroceptive, proprioceptive and sympathetic activity recorded with microelectrodes from human peripheral nerves. Mayo Clin Proc.. 1979;54:353-364.
22. Delwaide PJ. Human monosynaptic reflexes and presynaptic inhibition. In: Esmedt JE, ed. New Developments in Electromyography and Clinical Neurophysiology.. Basel, Switzerland: Karger; 1973:508-522.
23. McCouch GP. Sprouting as a cause of spasticity. J Neurophysiol.. 1958;21:205-216.
24. Cannon WB, Haimovici H. The sensitization of motorneurons by partial denervation. Am J Physiol.. 1939;126:731-740.
25. Willis WD. The raphe-spinal system. In: Barnes CD, ed. Brainstem Control of Spinal Cord Function.. New York, NY: Academic; 1984:141-214.
26. Sheean G. The pathophysiology of spasticity. Eur J Neurol.. 2002;9 (suppl 1):3-9.
27. Denny-Brown D. Historical aspects of the relation of spasticity to movement. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: Disordered Motor Control.. Chicago, IL: Yearbook Medical; 1980:1-16.
28. Gracies JM, Elovic E, McGuire J, et al. Traditional pharmacological treatments for spasticity. Part I: local treatments. In: Mayer NH, Simpson DM, eds. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin.. New York, NY: We Move; 2002:44-64.
29. Lund S, Lundberg A, Vyklicky L. Inhibitory action from the flexor reflex afferents on transmission to Ia afferents. Acta Physiol Scand.. 1965;64(4):345-355.
30. Zafonte RD, Elovic E. Spasticity and abnormalities of muscle tone. In: Grabois M, Garrison SJ, Hart KA, et al., eds. Physical Medicine & Rehabilitation: The Complete Approach.. Malden, MA: Blackwell Science; 2000:848-858.
31. Mirbagheri MM, Alibiglou L, Thajchayapong M, et al. Muscle and reflex changes with varying joint angle in hemiparetic stroke. J Neuroeng Rehabil.. 2008;5:6.
32. Mirbagheri MM, Rymer WZ, Tsao C, et al. Evolution of reflexive and muscular mechanical properties in stroke-induced spasticity. Conf Proc IEEE Eng Med Biol Soc.. 2005;4:4393-4395.
33. Gracies JM. Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. Phys Med Rehabil Clin N Am.. 2001;12(4):747-768, vi.
34. Ranson SW, Dixon HH. Elasticity and ductility of muscle in myostatic contracture caused by tetanus toxin. Am J Physiol.. 1928;86:312-319.
35. Williams RG. Sensitivity changes shown by spindle receptors in chronically immobilized skeletal muscle. J Physiol.. 1980;306:26-27.
36. Schmit BD, Dewald JP, Rymer WZ. Stretch reflex adaptation in elbow flexors during repeated passive movements in unilateral brain-injured patients. Arch Phys Med Rehabil.. 2000;81(3):269-278.
37. Wilson LR, Gracies JM, Burke D, et al. Evidence for fusimotor drive in stroke patients based on muscle spindle thixotropy. Neurosci Lett.. 1999;264(1-3):109-112.
38. Gracies JM, Marosszeky JE, Renton R, et al. Short-term effects of dynamic lycra splints on upper limb in hemiplegic patients. Arch Phys Med Rehabil.. 2000;81(12):1547-1555.
39. Tremblay F, Malouin F, Richards CL, et al. Effects of prolonged muscle stretch on reflex and voluntary muscle activations in children with spastic cerebral palsy. Scand J Rehabil Med.. 1990;22(4):171-180.
40. Carey JR. Manual stretch: effect on finger movement control and force control in stroke subjects with spastic extrinsic finger flexor muscles. Arch Phys Med Rehabil.. 1990;71(11):888-894.
41. Selles RW, Li X, Lin F, et al. Feedback-controlled and programmed stretching of the ankle plantarflexors and dorsiflexors in stroke: effects of a 4-week intervention program. Arch Phys Med Rehabil.. 2005;86(12): 2330-2336.
42. Brouwer B, Davidson LK, Olney SJ. Serial casting in idiopathic toe-walkers and children with spastic cerebral palsy. J Pediatr Orthop.. 2000;20(2):221-225.
43. Hill J. The effects of casting on upper extremity motor disorders after brain injury. Am J Occup Ther.. 1994;48(3):219-224.
44. Otis JC, Root L, Kroll MA. Measurement of plantar flexor spasticity during treatment with tone-reducing casts. J Pediatr Orthop.. 1985;5(6):682-686.
45. Booth BJ, Doyle M, Montgomery J. Serial casting for the management of spasticity in the head-injured adult. Phys Ther.. 1983;63(12):1960-1966.
46. Pohl M, Ruckriem S, Mehrholz J, et al. Effectiveness of serial casting in patients with severe cerebral spasticity: a comparison study. Arch Phys Med Rehabil.. 2002;83(6):784-790.
47. Farina S, Migliorini C, Gandolfi M, et al. Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke. Funct Neurol.. 2008;23(2):87-91.
48. Ackman JD, Russman BS, Thomas SS, et al. Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. Dev Med Child Neurol.. 2005;47(9):620-627.
49. Lightfoot E, Verrier M. Neurophysiological effects of prolonged cooling of the calf in patients with complete spinal cord transection. Physiotherapy.. 1976;62(4):114-117.
50. Weiss M, Duma-Drzewinska A. Cooling as a method of reducing spasticity. Neurol Neurochir Pol.. 1976;10(3):335-343.
51. Knutsson E. On effects of local cooling upon motor functions in spastic paresis. Prog Phys Ther.. 1970;1(2):124-131.
52. Knutsson E. Topical cryotherapy in spasticity. Scand J Rehabil Med.. 1970;2(4):159-163.
53. Gracies JM. Physical modalities other than stretch in spastic hypertonia. Phys Med Rehabil Clin N Am.. 2001;12(4):769-792, vi.
54. Bell KR, Lehmann JF. Effect of cooling on H- and T-reflexes in normal subjects. Arch Phys Med Rehabil.. 1987;68(8):490-493.
55. Douglas WW, Malcom JL. The effect of localized cooling on conduction in cat nerves. J Physiol.. 1955;130(1):53-71.
56. Lee JM, Warren MP. Ice, relaxation and exercise in reduction of muscle spasticity. Physiotherapy.. 1974;60(10):296-302.
57. Travell J. Ethyl chloride spray for painful muscle spasm. Arch Phys Med Rehabil.. 1952;33(5):291-298.
58. Lehmann JF, deLateur BJ. Diathermy and superficial heat and cold therapy. In: Krusen F, ed. Handbook of Physical Medicine.. Philadelphia, PA: WB Saunders;1996.
59. Warren CG, Lehmann JF, Koblanski JN. Heat and stretch procedures: an evaluation using rat tail tendon. Arch Phys Med Rehabil.. 1976;57(3):122-126.
60. Wessling KC, DeVane DA, Hylton CR. Effects of static stretch versus static stretch and ultrasound combined on triceps surae muscle extensibility in healthy women. Phys Ther.. 1987;67(5):674-679.
61. Bajd T, Gregoric M, Vodovnik L, et al. Electrical stimulation in treating spasticity resulting from spinal cord injury. Arch Phys Med Rehabil.. 1985;66(8):515-517.
62. Han JS, Chen XH, Yuan Y, et al. Transcutaneous electrical nerve stimulation for treatment of spinal spasticity. Chin Med J (Engl).. 1994;107(1):6-11.
63. Walker WC. Retraining the neuromuscular system: biofeedback and neuromuscular electrical stimulation. In: Grabois M, Garrison SJ, Hart KA, et al., eds. Physical Medicine & Rehabilitation: The Complete Approach.. Malden, MA: Blackwell Science; 2000:513-529.
64. Yan T, Hui-Chan CW, Li LS. Functional electrical stimulation improves motor recovery of the lower extremity and walking ability of subjects with first acute stroke: a randomized placebo-controlled trial. Stroke.. 2005;36(1):80-85.
65. Chen SC, Chen YL, Chen CJ, et al. Effects of surface electrical stimulation on the muscle-tendon junction of spastic gastrocnemius in stroke patients. Disabil Rehabil.. 2005;27(3):105-110.
66. Aydin G, Tomruk S, Keles I, et al. Transcutaneous electrical nerve stimulation versus baclofen in spasticity: clinical and electrophysiologic comparison. Am J Phys Med Rehabil.. 2005;84(8):584-592.
67. Bakhtiary AH, Fatemy E. Does electrical stimulation reduce spasticity after stroke? A randomized controlled study. Clin Rehabil.. 2008;22(5):418-425.
68. Khalili MA, Hajihassanie A. Electrical simulation in addition to passive stretch has a small effect on spasticity and contracture in children with cerebral palsy: a randomised within-participant controlled trial. Aust J Physiother.. 2008;54(3):185-189.
69. Xu KS, He L, Li JL, et al. Effects of transcutaneous electrical nerve stimulation on motor function in ambulant children with spastic cerebral palsy: a randomized trial. Zhonghua Er Ke Za Zhi.. 2007;45(8): 564-567.
70. Krause P, Szecsi J, Straube A. FES cycling reduces spastic muscle tone in a patient with multiple sclerosis. NeuroRehabilitation.. 2007;22(4): 335-337.
71. Elovic E. Principles of pharmaceutical management of spastic hypertonia. Phys Med Rehabil Clin N Am.. 2001;12(4):793-816, vii.
72. Elovic E, Zafonte RD. Spasticity management in traumatic brain injury. State Art Rev Rehabil.. 2001;15(2):327-348.
73. Duncan GW, Shahani BT, Young RR. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study. Neurology.. 1976;26(5):441-446.
74. Hudgson P, Weightman D. Baclofen in the treatment of spasticity. Br Med J.. 1971;4(778):15-17.
75. Nance PW, Bugaresti J, Shellenberger K, et al. North American Tizanidine Study Group. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology.. 1994; 44(11 suppl 9):S44-S51.
76. Kirshblum S. Treatment alternatives for spinal cord injury related spasticity. J Spinal Cord Med.. 1999;22(3):199-217.
77. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther.. 1998;15(4):241-251.
78. Goldstein LB. The Sygen in Acute Stroke Study Investigators. Common drugs may influence motor recovery after stroke. Neurology.. 1995;45(5):865-871.
79. Meythaler JM, Guin-Renfroe S, Johnson A, et al. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil.. 2001;82(9):1155-1163.
80. Francois B, Vacher P, Roustan J, et al. Intrathecal baclofen after traumatic brain injury: early treatment using a new technique to prevent spasticity. J Trauma.. 2001;50(1):158-161.
81. Gracies JM, Elovic E, McGuire J, et al. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. In: Mayer NH, Simpson DM, eds. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin.. New York, NY: We Move; 2002:65-93.
82. Tseng TC, Wang SC. Locus of action of centrally acting muscle relaxants, diazepam and tybamate. J Pharmacol Exp Ther.. 1971;178(2):350-360.
83. Lossius R, Dietrichson P, Lunde PK. Effect of clorazepate in spasticity and rigidity: a quantitative study of reflexes and plasma concentrations. Acta Neurol Scand.. 1985;71(3):190-194.
84. Scharf MB, Hirschowitz J, Woods M, et al. Lack of amnestic effects of clorazepate on geriatric recall. J Clin Psychiatry.. 1985;46(12):518-520.
85. Abernethy DR, Greenblatt DJ, Divoll M, et al. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). J Pharm Sci.. 1982;71(8):942-944.
86. Corbett M, Frankel HL, Michaelis L. A double blind, cross-over trial of Valium in the treatment of spasticity. Paraplegia.. 1972;10(1):19-22.
87. Whyte J, Robinson KM. Pharmacologic management. In: Glenn MB, Whyte J, eds. The Practical Management of Spasticity in Children and Adults.. Malvern, PA: Lea & Febiger; 1990:201-226.
88. Verrier M, Ashby P, MacLeod S. Diazepam effect on reflex activity in patients with complete spinal lesions and in those with other causes of spasticity. Arch Phys Med Rehabil.. 1977;58(4):148-153.
89. Cook JB, Nathan PW. On the site of action of diazepam in spasticity in man. J Neurol Sci.. 1967;5(1):33-37.
90. Broderick CP, Radnitz CL, Bauman WA. Diazepam usage in veterans with spinal cord injury. J Spinal Cord Med.. 1997;20(4):406-409.
91. Cartlidge NE, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci.. 1974;23(1):17-24.
92. From A, Heltberg A. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand.. 1975;51(2):158-166.
93. Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapeutica.. 1985;4(5):278-284.
94. Engle HA. The effect of diazepam (Valium) in children with cerebral palsy: a double-blind study. Dev Med Child Neurol.. 1966;8:661-667.
95. Mathew A, Mathew MC. Bedtime diazepam enhances well-being in children with spastic cerebral palsy. Pediatr Rehabil.. 2005;8(1):63-66.
96. Nogen AG. Medical treatment for spasticity in children with cerebral palsy. Childs Brain.. 1976;2(5):304-308.
97. Cruikshank M, Eunson P. Intravenous diazepam infusion in the management of planned intrathecal baclofen withdrawal. Dev Med Child Neurol.. 2007;49(8):626-628.
98. Basmajian JV. Lioresal (baclofen) treatment of spasticity in multiple sclerosis. Am J Phys Med.. 1975;54(4):175-177.
99. Nance PW. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc.. 1994;17(3):150-156.
100. Feldman RG, Kelly-Hayes M, Conomy JP, et al. Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology.. 1978;28(11):1094-1098.
101. Hedley DW, Maroun JA, Espir ML. Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis. Postgrad Med J.. 1975;51(599):615-618.
102. Basmajian JV, Yucel V. Effects of a GABA-derivative (BA-34647) on spasticity. Preliminary report of a double-blind cross-over study. Am J Phys Med.. 1974;53(5):223-228.
103. Jones RF, Lance JW. Bacloffen (Lioresal) in the long-term management of spasticity. Med J Aust.. 1976;1(18):654-657.
104. Pedersen E, Arlien-Soborg P, Grynderup V, et al. GABA derivative in spasticity. (Beta-(4-chlorophenyl)-gamma-aminobutyric acid, Ciba 34.647-Ba). Acta Neurol Scand.. 1970;46(3):257-266.
105. Ashby P, White DG. "Presynaptic" inhibition in spasticity and the effect of beta(4-chlorophenyl)GABA. J Neurol Sci.. 1973;20(3):329-338.
106. Orsnes GB, Sorensen PS, Larsen TK, et al. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand.. 2000;101(4):244-248.
107. Nielsen JF, Anderson JB, Sinkjaer T. Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients. Mult Scler.. 2000;6(2):105-114.
108. Nielsen JF, Sinkjaer T. Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis. Muscle Nerve.. 2000;23(1):98-105.
109. Pedersen E. Clinical assessment and pharmacologic therapy of spasticity. Arch Phys Med Rehabil.. 1974;55(8):344-354.
110. Pinto OS, Polikar M, Debono G. Results of international clinical trials with Lioresal. Postgrad Med J.. 1972;48(suppl 25):18-25.
111. Hulme A, MacLennan WJ, Ritchie RT, et al. Baclofen in the elderly stroke patient its side-effects and pharmacokinetics. Eur J Clin Pharmacol.. 1985;29(4):467-469.
112. Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res.. 1977;5(6):398-404.
113. van DJ, Kukke S, McGill K, et al. Oral baclofen increases maximal voluntary neuromuscular activation of ankle plantar flexors in children with spasticity due to cerebral palsy. J Child Neurol.. 2008;23(6):635-639.
114. Katz RT, Campagnolo DI. Pharmacologic management of spasticity. In: Katz RT, ed. Spasticity: State of the Arts Review.. Philadelphia, PA: Hanley & Belfus; 1994:473-480.
115. Utili R, Boitnott JK, Zimmerman HJ. Dantrolene associated hepatic injury: incidence and character. Gastroenterology.. 1977;72:610.
116. Zafonte R, Lombard L, Elovic E. Antispasticity medications: uses and limitations of enteral therapy. Am J Phys Med Rehabil.. 2004;83(10 suppl):S50-S58.
117. Krause T, Gerbershagen MU, Fiege M, et al. Dantrolene-a review of its pharmacology, therapeutic use and new developments. Anaesthesia.. 2004;59(4):364-373.
118. Chua KS, Kong KH. An unusual case of Dantrolene sodium-induced urinary retention in post-traumatic minimally responsive state. Brain Inj.. 2005;19(12):1063-1066.
119. Glass A, Hannah A. A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Paraplegia.. 1974;12(3):170-174.
120. Weiser R, Terenty T, Hudgson P, et al. Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. Practitioner.. 1978;221(1321):123-127.
121. Monster AW. Spasticity and the effect of dantrolene sodium. Arch Phys Med Rehabil.. 1974;55(8):373-383.
122. Mandac BR, Hurvitz EA, Nelson VS. Hyperthermia associated with baclofen withdrawal and increased spasticity. Arch Phys Med Rehabil.. 1993;74(1):96-97.
123. Khorasani A, Peruzzi WT. Dantrolene treatment for abrupt intrathecal baclofen withdrawal. Anesth Analg.. 1995;80(5):1054-1056.
124. Taricco M, Pagliacci MC, Telaro E, et al. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review. Eura Medicophys.. 2006;42(1):5-15.
125. Gelenberg AJ, Poskanzer DC. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology.. 1973;23(12):1313-1315.
126. Tolosa ES, Soll RW, Loewenson RB. Letter: treatment of spasticity in multiple sclerosis with dantrolene. JAMA.. 1975;233(10):1046.
127. Chyatte SB, Birdsong JH, Bergman BA. The effects of dantrolene sodium on spasticity and motor performance in hemiplegia. South Med J.. 1971;64(2):180-185.
128. Ketel WB, Kolb ME. Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function. Curr Med Res Opin.. 1984;9(3):161-169.
129. Krach LE. Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. J Child Neurol.. 2001;16(1):31-36.
130. Haslam RH, Walcher JR, Lietman PS, et al. Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil.. 1974;55(8):384-388.
131. Verrotti A, Greco R, Spalice A, et al. Pharmacotherapy of spasticity in children with cerebral palsy. Pediatr Neurol.. 2006;34(1):1-6.
132. Donovan WH, Carter RE, Rossi CD, et al. Clonidine effect on spasticity: a clinical trial. Arch Phys Med Rehabil.. 1988;69(3 pt 1):193-194.
133. Nance PW, Shears AH, Nance DM. Clonidine in spinal cord injury. Can Med Assoc J.. 1985;133(1):41-42.
134. Nance PW, Shears AH, Nance DM. Reflex changes induced by clonidine in spinal cord injured patients. Paraplegia.. 1989;27(4):296-301.
135. Rosenblum D. Clonidine-induced bradycardia in patients with spinal cord injury. Arch Phys Med Rehabil.. 1993;74(11):1206-1207.
136. Weingarden SI, Belen JG. Clonidine transdermal system for treatment of spasticity in spinal cord injury. Arch Phys Med Rehabil.. 1992;73(9): 876-877.
137. Yablon SA, Sipski ML. Effect of transdermal clonidine on spinal spasticity. A case series. Am J Phys Med Rehabil.. 1993;72(3):154-157.
138. Lubsch L, Habersang R, Haase M, et al. Oral baclofen and clonidine for treatment of spasticity in children. J Child Neurol.. 2006;21(12):1090-1092.
139. Sandford PR, Spengler SE, Sawasky KB. Clonidine in the treatment of brainstem spasticity. Case report. Am J Phys Med Rehabil.. 1992;71(5):301-303.
140. Dall JT, Harmon RL, Quinn CM. Use of clonidine for treatment of spasticity arising from various forms of brain injury: a case series. Brain Inj.. 1996;10(6):453-458.
141. Davies J, Johnston SE. Selective antinociceptive effects of tizanidine (DS 103-282), a centrally acting muscle relaxant, on dorsal horn neurones in the feline spinal cord. Br J Pharmacol.. 1984;82(2):409-421.
142. Davies J, Johnston SE, Hill DR, et al. Tizanidine (DS103-282), a centrally acting muscle relaxant, selectively depresses excitation of feline dorsal horn neurones to noxious peripheral stimuli by an action at alpha 2-adrenoceptors. Neurosci Lett.. 1984;48(2):197-202.
143. Kameyama T, Nabeshima T, Sugimoto A, et al. Antinociceptive action of tizanidine in mice and rats. Naunyn Schmiedebergs Arch Pharmacol.. 1985;330(2):93-96.
144. Newman PM, Nogues M, Newman PK, et al. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol.. 1982;23(1):31-35.
145. Bass B, Weinshenker B, Rice GP, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci.. 1988;15(1):15-19.
146. Bes A, Eyssette M, Pierrot-Deseilligny E, et al. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin.. 1988;10(10):709-718.
147. Lapierre Y, Bouchard S, Tansey C, et al. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci.. 1987;14(3 suppl):513-517.
148. Johnson TR, Tobias JD. Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension. J Child Neurol.. 2000;15(12):818-819.
149. Mathias CJ, Luckitt J, Desai P, et al. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev.. 1989;26(4):9-16.
150. Smith C, Birnbaum G, Carter JL, et al. US Tizanidine Study Group. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. Neurology.. 1994;44(11 suppl 9):S34-S42.
151. Eyssette M, Rohmer F, Serratrice G, et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin.. 1988;10(10):699-708.
152. United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology.. 1994;44(11 suppl 9):S70-S78.
153. Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother.. 2008;9(12):2209-2215.
154. Kamen L, Henney HR Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin.. 2008;24(2):425-439.
155. Simpson DM, Gracies JM, Yablon SM, et al. Botulinum neurotoxin vs tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry.. 2009;80:380-385.
156. Brin IL, Kurenkov AL, Gotlib VI. The use of sirdalud in cerebral palsy in children. Zh Nevrol Psikhiatr Im S S Korsakova.. 1999;99(10):30-33.
157. Vasquez-Briceno A, Arellano-Saldana ME, Leon-Hernandez SR, et al. The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy. Rev Neurol.. 2006;43(3):132-136.
158. Maritz NG, Muller FO, Pompe van Meerdervoort HF. Piracetam in the management of spasticity in cerebral palsy. S Afr Med J.. 1978;53(22):889-891.
159. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature.. 2000;404(6773):84-87.
160. Petro DJ, Ellenberger C Jr. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol.. 1981;21(8-9 suppl):413S-416S.
161. Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol.. 2007;14(3):290-296.
162. Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil.. 2000;81(2):164-169.
163. Dunevsky A, Perel AB. Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehabil.. 1998;77(5):451-454.
164. Gruenthal M, Mueller M, Olson WL, et al. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord.. 1997;35(10):686-689.
165. Mueller ME, Gruenthal M, Olson WL, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil.. 1997;78(5):521-524.
166. Priebe MM, Sherwood AM, Graves DE, et al. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord.. 1997;35(3):171-175.
167. Kitzman PH, Uhl TL, Dwyer MK. Gabapentin suppresses spasticity in the spinal cord-injured rat. Neuroscience.. 2007;149(4):813-821.
168. Holden KR, Titus MO. The effect of tiagabine on spasticity in children with intractable epilepsy: a pilot study. Pediatr Neurol.. 1999;21(4):728-730.
169. Davies SL, Moral MA. Clinical development of levetiracetam for amyotrophic lateral sclerosis. Drug News Perspect.. 2006;19(9):572-573.
170. Ruegg SJ, Steck AJ, Fuhr P. Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology.. 2004;62(2):338.
171. Hawker K, Frohman E, Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol.. 2003;60(12):1772-1774.
172. Bradley LJ, Kirker GB. Pregabalin in the treatment of spasticity: a restrospective case series. Disabil Rehabil.. 2008;30(16):1230-1232.
173. Hurst DL, Lajara-Nanson W. Use of modafinil in spastic cerebral palsy. J Child Neurol.. 2002;17(3):169-172.
174. Hurst DL, Lajara-Nanson WA, Dinakar P, et al. Retrospective review of modafinil use for cerebral palsy. J Child Neurol.. 2004;19(12):948-951.
175. Glenn MB. Nerve blocks. In: Glenn MB, Whyte J, eds. The Practical Management of Spasticity in the Adult and Child.. Philadelphia, PA: Lea & Febiger; 1990:227-258.
176. Autti-Ramo I, Larsen A, Peltonen J, et al. Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia. Neuropediatrics.. 2000;31(1):4-8.
177. Glenn MB. Nerve blocks for the treatment of spasticity. In: Katz RT, ed. Spasticity: State of the Arts Review.. Philadelphia, PA: Hanley & Belfus; 1994:481-505.
178. Tilton AH. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. J Child Neurol.. 2003;18(suppl 1):S50-S66.
179. Cullu E, Ozkan I, Culhaci N, et al. A comparison of the effect of doxorubicin and phenol on the skeletal muscle. May doxorubicin be a new alternative treatment agent for spasticity? J Pediatr Orthop B.. 2005;14(2):134-138.
180. Glenn MB, Elovic E. Chemical denervation for the treatment of hypertonia and related disorders: phenol and Botulinum toxin. J Head Trauma Rehabil.. 1997;12(6):40-62.
181. Setler P. The biochemistry of botulinum toxin type B. Neurology.. 2000;55(12 suppl 5):S22-S28.
182. Khalili AA, Harmel MH, Forster S, et al. Management of spasticity by selective peripheral nerve block with dilute phenol solutions in clinical rehabilitation. Arch Phys Med Rehabil.. 1964;45:513-519.
183. Halpern D, Meelhuysen FE. Phenol motor point block in the management of muscular hypertonia. Arch Phys Med Rehabil.. 1966;47(10):659-664.
184. DeLateur BJ. A new technique of intramuscular phenol neurolysis. Arch Phys Med Rehabil.. 1972;53(4):179-181.
185. Awad EA. Phenol block for control of hip flexor and adductor spasticity. Arch Phys Med Rehabil.. 1972;53(12):554-557.
186. Chua KS, Kong KH. Alcohol neurolysis of the sciatic nerve in the treatment of hemiplegic knee flexor spasticity: clinical outcomes. Arch Phys Med Rehabil.. 2000;81(10):1432-1435.
187. Chua KS, Kong KH. Clinical and functional outcome after alcohol neurolysis of the tibial nerve for ankle-foot spasticity. Brain Inj.. 2001;15(8):733-739.
188. Kong KH, Chua KS. Outcome of obturator nerve block with alcohol for the treatment of hip adductor spasticity. Int J Rehabil Res.. 1999;22(4):327-329.
189. Koman LA, Mooney JF Smith BP. Neuromuscular blockade in the management of cerebral palsy. J Child Neurol.. 1996;11(suppl 1):S23-S28.
190. Garland DE, Lucie RS, Waters RL. Current uses of open phenol nerve block for adult acquired spasticity. Clin Orthop.. 1982;165:217-222.
191. Moore TJ, Anderson RB. The use of open phenol blocks to the motor branches of the tibial nerve in adult acquired spasticity. Foot Ankle.. 1991;11(4):219-221.
192. Spira R. Management of spasticity in cerebral palsied children by peripheral nerve block with phenol. Dev Med Child Neurol.. 1971;13(2):164-173.
193. Gooch JL, Patton CP. Combining botulinum toxin and phenol to manage spasticity in children. Arch Phys Med Rehabil.. 2004;85(7):1121-1124.
194. Lee J, Lee YS. Percutaneous chemical nerve block with ultrasound-guided intraneural injection. Eur Radiol.. 2008;18(7):1506-1512.
195. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers'product summaries. J Clin Pharm Ther.. 2007;32(4):387-402.
196. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part Am J Health Syst Pharm.. 2006;63(2):145-152.
197. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part Am J Health Syst Pharm.. 2006;63(3):225-232.
198. Jost WH. Botulinum toxin in multiple sclerosis. J Neurol.. 2006;253(suppl 1):I16-I20.
199. Maan Z, Al-Singary W, Shergill I, et al. Alternative use of botulinum toxin in urology. Expert Opin Pharmacother.. 2004;5(5):1015-1021.
200. Smith CP, Somogyi GT, Boone TB. Botulinum toxin in urology: evaluation using an evidence-based medicine approach. Nat Clin Pract Urol.. 2004;1(1):31-37.
201. Lim JY, Koh JH, Paik NJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke.. 2008;39(1): 126-131.
202. Yelnik AP, Colle FM, Bonan IV, et al. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A. J Neurol Neurosurg Psychiatry.. 2007;78(8):845-848.
203. Chang H. Botulism toxin: use in disorders of the temporomandibular joint. Dent Today.. 2005;24(12):48, 50-51.
204. Clark GT. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. Phys Med Rehabil Clin N Am.. 2003;14(4):727-748.
205. Scholtes VA, Dallmeijer AJ, Knol DL, et al. Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy. Pediatr Neurol.. 2007;36(1):30-39.
206. Pieper C. Botulinum toxin type a neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. Pediatr Phys Ther.. 2001;13(2):92-94.
207. Opara J, Hordynska E, Swoboda A. Effectiveness of botulinum toxin A in the treatment of spasticity of the lower extremities in adults-preliminary report. Ortop Traumatol Rehabil.. 2007;9(3):277-285.
208. Marciniak C, Rader L, Gagnon C. The use of botulinum toxin for spasticity after spinal cord injury. Am J Phys Med Rehabil.. 2008;87(4):312-317.
209. Lagalla G, Danni M, Reiter F, et al. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil.. 2000;79(4):377-384.
210. Jahangir AW, Tan HJ, Norlinah MI, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. Med J Malaysia.. 2007;62(4):319-322.
211. Hawamdeh ZM, Ibrahim AI, Al-Qudah AA. Long-term effect of botulinum toxin (A) in the management of calf spasticity in children with diplegic cerebral palsy. Eura Medicophys.. 2007;43(3):311-318.
212. Gordon MF, Brashear A, Elovic E, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology.. 2004;63(10):1971-1973.
213. Giovannelli M, Borriello G, Castri P, et al. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil.. 2007;21(4):331-337.
214. Gibson N, Graham HK, Love S. Botulinum toxin A in the management of focal muscle overactivity in children with cerebral palsy. Disabil Rehabil.. 2007;29(23):1813-1822.
215. Esquenazi A, Mayer N, Garreta R. Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait. Am J Phys Med Rehabil.. 2008;87(4):305-310.
216. Elovic EP, Brashear A, Kaelin D, et al. Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil.. 2008;89(5):799-806.
217. Criswell SR, Crowner BE, Racette BA. The use of botulinum toxin therapy for lower-extremity spasticity in children with cerebral palsy. Neurosurg Focus.. 2006;21(2):e1.
218. Cardoso ES, Rodrigues BM, Barroso M, et al. Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy. Pediatr Neurol.. 2006;34(2):106-109.
219. Bhakta BB, O'Connor RJ, Cozens JA. Associated reactions after stroke: a randomized controlled trial of the effect of botulinum toxin type A. J Rehabil Med.. 2008;40(1):36-41.
220. Ashford S, Turner-Stokes L. Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: a preliminary analysis of goals and outcomes. Disabil Rehabil.. 2009;31:220-226.
221. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med.. 2002;347(6):395-400.
222. Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol.. 1990;28(4):512-515.
223. Yablon SA, Agana BT, Ivanhoe CB, et al. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology.. 1996;47(4):939-944.
224. Wilson DJ, Childers MK, Cooke DL, et al. Kinematic changes following botulinum toxin injection after traumatic brain injury. Brain Inj.. 1997;11(3):157-167.
225. Richardson D, Sheean G, Werring D, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry.. 2000;69(4):499-506.
226. Ozcakir S, Sivrioglu K. Botulinum toxin in poststroke spasticity. Clin Med Res.. 2007;5(2):132-138.
227. Simpson DM, Gracies JM, Yablon SM, et al. Botulinum neurotoxin vs tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry.. 2009;80:380-385.
228. Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology.. 2008;70(19):1691-1698.
229. Baker R, Jasinski M, Iag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol.. 2002;44(10):666-675.
230. Moore AP, de-Hall RA, Smith CT, et al. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology.. 2008;71(2):122-128.
231. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry.. 2000;68(6):707-712.
232. Brashear A, McAfee AL, Kuhn ER, et al. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil.. 2004;85(5):705-709.
233. Racette BA, Gee-Minnich L, Perlmutter JS. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation. Clin Neuropharmacol.. 1999;22(6):337-339.
234. Racette BA, Stambuk M, Perlmutter JS. Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024). Mov Disord.. 2002;17(5):1098-1100.
235. Clinical use of botulinum toxin. National Institutes of Health Consensus Development Conference Statement, November 12-14, Arch Neurol.. 1991;48(12):1294-1298.
236. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord.. 1988;3(4):333-335.
237. FDA Issues Complete Response Letter To Ipsen For Dysport® Biologics License Application For Treatment Of Cervical Dystonia. Available at: http://www.medicalnewstoday.com/articles/134294.php. Accessed April 13, 2009.
238. Bakheit AM, Sawyer J. The effects of botulinum toxin treatment on associated reactions of the upper limb on hemiplegic gait-a pilot study. Disabil Rehabil.. 2002;24(10):519-522.
239. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol.. 2001;8(6):559-565.
240. Hesse S, Brandi-Hesse B, Bardeleben A, et al. Botulinum toxin A treatment of adult upper and lower limb spasticity. Drugs Aging.. 2001;18(4):255-262.
241. Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke.. 2000;31(10):2402-2406.
242. Bhakta BB, Cozens JA, Chamberlain MA, et al. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry.. 2000;69(2):217-221.
243. Watanabe Y, Bakheit AM, McLellan DL. A study of the effectiveness of botulinum toxin type A (Dysport) in the management of muscle spasticity. Disabil Rehabil.. 1998;20(2):62-65.
244. Rodgers H, Shaw L, Price C, et al. Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Trials.. 2008;9(1):59.
245. Barnes M. Botulinum toxin-mechanisms of action and clinical use in spasticity. J Rehabil Med.. 2003;(41 suppl):56-59.
246. BeDell K, Plant K, Forcier S. Use of botulinum toxin type B for the treatment of spasticity in a child with severe spastic quadriplegic cerebral palsy: a case report. Arch Phys Med Rehabil.. 2002;83(10):1675.
247. Hecht JS, Preston LA, McPhee S. Effects of botulinum toxin type B on shoulder pain, hyperonia and function in adults with spastic hemiparesis. Arch Phys Med Rehabil.. 2002;83:1690.
248. Jayasooriaya SM, Francisco GE, Healy W. Early experience with the use of Myobloc (botulinum toxin type b) for the treatment of upper limb spastic hypertonia. Arch Phys Med Rehabil.. 2002;83(10):1677.
249. Moberg-Wolff EA, Walke K. Use of botulinum toxin type B in the pediatric population. Arch Phys Med Rehabil.. 2002;83(10):1673.
250. Barnes MP, Best D, Kidd L, et al. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A-initial experiences. Eur J Neurol.. 2005;12(12):947-955.
251. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology.. 2005;65(9):1423-1429.
252. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord.. 1994;9(2):213-217.
253. Zuber M, Sebald M, Bathien N, et al. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology.. 1993;43(9):1715-1718.
254. Herrmann J, Geth K, Mall V, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol.. 2004;55(5):732-735.
255. Yablon SA, Brashear A, Gordon MF, et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther.. 2007;29(4):683-690.
256. Turkel CC, Bowen B, Liu J, et al. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil.. 2006;87(6):786-792.
257. Crowner BE, Brunstrom JE, Racette BA. Iatrogenic botulism due to therapeutic botulinum toxin a injection in a pediatric patient. Clin Neuropharmacol.. 2007;30(5):310-313.
258. Rossi RP, Strax TE, Di RA. Severe dysphagia after botulinum toxin B injection to the lower limbs and lumbar paraspinal muscles. Am J Phys Med Rehabil.. 2006;85(12):1011-1013.
259. Brueggemann N, Doegnitz L, Harms L, et al. Skin reactions after intramuscular injection of Botulinum toxin A: a rare side effect. J Neurol Neurosurg Psychiatry.. 2008;79(2):231-232.
260. Dubow J, Kim A, Leikin J, et al. Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections. Mov Disord.. 2005;20(7):877-880.
261. FDA. Early Communication about an Ongoing Safety Review Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B). 2-28-12-21-0008.
262. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med.. 1989;320(23):1517-1521.
263. Albright AL, Barron WB, Fasick MP, et al. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA.. 1993;270(20): 2475-2477.
264. Meythaler JM, Guin-Renfroe S, Grabb P, et al. Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. Arch Phys Med Rehabil.. 1999;80(1):13-19.
265. Becker R, Alberti O, Bauer BL. Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. J Neurol.. 1997;244(3):160-166.
266. Gwartz BL. Intrathecal baclofen for spasticity caused by thrombotic stroke. Am J Phys Med Rehabil.. 2001;80(5):383-387.
267. Meythaler JM, Guin-Renfroe S, Brunner RC, et al. Intrathecal baclofen for spastic hypertonia from stroke. Stroke.. 2001;32(9):2099-2109.
268. Ivanhoe CB, Francisco GE, McGuire JR, et al. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil.. 2006;87(11):1509-1515.
269. Francisco GE, Yablon SA, Schiess MC, et al. Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. Top Stroke Rehabil.. 2006;13(4):74-85.
270. Guillaume D, Van HA, Vloeberghs M, et al. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. Arch Phys Med Rehabil.. 2005;86(11):2165-2171.
271. Panourias IG, Themistocleous M, Sakas DE. Intrathecal baclofen in current neuromodulatory practice: established indications and emerging applications. Acta Neurochir Suppl.. 2007;97(pt 1):145-154.
272. Bleyenheuft C, Filipetti P, Caldas C, et al. Experience with external pump trial prior to implantation for intrathecal baclofen in ambulatory patients with spastic cerebral palsy. Neurophysiol Clin.. 2007;37(1):23-28.
273. Dralle D, Muller H, Zierski J, et al. Intrathecal baclofen for spasticity [letter]. Lancet.. 1985;2(8462):1003.
274. Bucholz RD. Management of intractable spasticity with intrathecal baclofen. In: Katz RT, ed. Spasticity: State of the Arts Review.. Philadelphia, PA: Hanley & Belfus; 1994:565-578.
275. Steinbok P, Daneshvar H, Evans D, et al. Cost analysis of continuous intrathecal baclofen versus selective functional posterior rhizotomy in the treatment of spastic quadriplegia associated with cerebral palsy. Pediatr Neurosurg.. 1995;22(5):255-264.
276. Teddy P, Jamous A, Gardner B, et al. Complications of intrathecal baclofen delivery. Br J Neurosurg.. 1992;6(2):115-118.
277. Albright AL, Ferson SS. Intrathecal baclofen therapy in children. Neurosurg Focus.. 2006;21(2):e3.
278. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg.. 1992;77(2):236-240.
279. Kofler M, Kronenberg MF, Rifici C, et al. Epileptic seizures associated with intrathecal baclofen application. Neurology.. 1994;44(1):25-27.
280. Green LB, Nelson VS. Death after acute withdrawal of intrathecal baclofen: case report and literature review. Arch Phys Med Rehabil.. 1999;80(12):1600-1604.
281. Reeves RK, Stolp-Smith KA, Christopherson MW. Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure. Arch Phys Med Rehabil.. 1998;79(3): 353-356.
282. Ginsburg GM, Lauder AJ. Progression of scoliosis in patients with spastic quadriplegia after the insertion of an intrathecal baclofen pump. Spine.. 2007;32(24):2745-2750.
283. Sansone JM, Mann D, Noonan K, et al. Rapid progression of scoliosis following insertion of intrathecal baclofen pump. J Pediatr Orthop.. 2006;26(1):125-128.
284. Senaran H, Shah SA, Presedo A, et al. The risk of progression of scoliosis in cerebral palsy patients after intrathecal baclofen therapy. Spine.. 2007;32(21):2348-2354.
285. Ivanhoe CB, Tilton AH, Francisco GE. Intrathecal baclofen therapy for spastic hypertonia. Phys Med Rehabil Clin N Am.. 2001;12(4):923-938.
286. Grabb PA, Guin-Renfroe S, Meythaler JM. Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. Neurosurgery.. 1999;45(4):833-836.
287. Broseta J, Garcia-March G, Sanchez-Ledesma MJ, et al. Chronic intrathecal baclofen administration in severe spasticity. Stereotact Funct Neurosurg.. 1990;54-55:147-153.
288. Middleton JW, Siddall PJ, Walker S, et al. Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study. Arch Phys Med Rehabil.. 1996;77(8): 824-826.
289. Remy-Neris O, Denys P, Bussel B. Intrathecal clonidine for controlling spastic hypertonia. Phys Med Rehabil Clin N Am.. 2001;12(4):939-951, ix.
290. Chabal C, Jacobson L, Terman G. Intrathecal fentanyl alleviates spasticity in the presence of tolerance to intrathecal baclofen. Anesthesiology.. 1992;76(2):312-314.
291. Chabal C, Jacobson L, Schwid HA. An objective comparison of intrathecal lidocaine versus fentanyl for the treatment of lower extremity spasticity. Anesthesiology.. 1991;74(4):643-646.
292. Muller H, Gerlach H, Boldt J, et al. Spasticity treatment with spinal morphine or midazolam. In vitro experiments, animal studies and clinical studies on compatibility and effectiveness. Anaesthesist.. 1986;35(5):306-316.
293. Malinovsky JM, Cozian A, Lepage JY, et al. Ketamine and midazolam neurotoxicity in the rabbit. Anesthesiology.. 1991;75(1):91-97.
294. Erdine S, Yucel A, Ozyalcin S, et al. Neurotoxicity of midazolam in the rabbit. Pain.. 1999;80(1-2):419-423.
295. Bahar M, Cohen ML, Grinshpoon Y, et al. An investigation of the possible neurotoxic effects of intrathecal midazolam combined with fentanyl in the rat. Eur J Anaesthesiol.. 1998;15(6):695-701.
296. Canavero S, Bonicalzi V, Clemente M. No neurotoxicity from long-term (>5 years) intrathecal infusion of midazolam in humans. J Pain Symptom Manage.. 2006;32(1):1-3.
297. Malinovsky JM. Is intrathecal midazolam safe? Can J Anaesth.. 1997; 44(12):1321-1322.
298. Yaksh TL, Allen JW. The use of intrathecal midazolam in humans: a case study of process [table]. Anesth Analg.. 2004;98(6):1536-1545.
299. Erickson DL, Lo J, Michaelson M. Control of intractable spasticity with intrathecal morphine sulfate. Neurosurgery.. 1989;24(2):236-238.
300. Erickson DL, Blacklock JB, Michaelson M, et al. Control of spasticity by implantable continuous flow morphine pump. Neurosurgery.. 1985;16(2):215-217.
301. Sadiq SA, Poopatana CA. Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. J Neurol.. 2007;254(10): 1464-1465.
302. Vidal J, Gregori P, Guevara D, et al. Efficacy of intrathecal morphine in the treatment of baclofen tolerance in a patient on intrathecal baclofen therapy (ITB). Spinal Cord.. 2004;42(1):50-51.
303. Lydon AM, Cooke T, Duggan F, et al. Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. Can J Anaesth.. 1999;46(6):544-549.
304. Glass PS. Respiratory depression following only 0.4 mg of intrathecal morphine. Anesthesiology.. 1984;60(3):256-257.
305. Remy-Neris O, Barbeau H, Daniel O, et al. Effects of intrathecal clonidine injection on spinal reflexes and human locomotion in incomplete paraplegic subjects. Exp Brain Res.. 1999;129(3):433-440.
306. Chartier-Kastler E, Azouvi P, Yakovleff A, et al. Intrathecal catheter with subcutaneous port for clonidine test bolus injection. A new route and type of treatment for detrusor hyperreflexia in spinal cord-injured patients. Eur Urol.. 2000;37(1):14-17.
307. Denys P, Chartier-Kastler E, Azouvi P, et al. Intrathecal clonidine for refractory detrusor hyperreflexia in spinal cord injured patients: a preliminary report. J Urol.. 1998;160(6 pt 1):2137-2138.
308. Kroin JS, McCarthy RJ, Penn RD, et al. Intrathecal clonidine and tizanidine in conscious dogs: comparison of analgesic and hemodynamic effects. Anesth Analg.. 1996;82(3):627-635.
309. Boscarino LF, Ounpuu S, Davis RB et al. Effects of selective dorsal rhizotomy on gait in children with cerebral palsy. J Pediatr Orthop.. 1993;13(2):174-179.
310. Gul SM, Steinbok P, McLeod K. Long-term outcome after selective posterior rhizotomy in children with spastic cerebral palsy. Pediatr Neurosurg.. 1999;31(2):84-95.
311. Hodgkinson I, Berard C, Jindrich ML, et al. Selective dorsal rhizotomy in children with cerebral palsy. Results in 18 cases at one year postoperatively. Stereotact Funct Neurosurg.. 1997;69(1-4 pt 2):259-267.
312. Wright FV, Sheil EM, Drake JM, et al. Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: a randomized controlled trial. Dev Med Child Neurol.. 1998;40(4):239-247.
313. Morrison G, Yashon D, White RJ. Relief of pain and spasticity by anterior dorsolumbar rhizotomy in multiple sclerosis. Ohio State Med J.. 1969;65(6):588-591.
314. Sindou M, Millet MF, Mortamais J, et al. Results of selective posterior rhizotomy in the treatment of painful and spastic paraplegia secondary to multiple sclerosis. Appl Neurophysiol.. 1982;45(3):335-340.
315. Kasdon DL, Lathi ES. A prospective study of radiofrequency rhizotomy in the treatment of posttraumatic spasticity. Neurosurgery.. 1984;15(4):526-529.
316. Sindou M, Mifsud JJ, Boisson D, et al. Selective posterior rhizotomy in the dorsal root entry zone for treatment of hyperspasticity and pain in the hemiplegic upper limb. Neurosurgery.. 1986;18(5):587-595.
317. Sindou M, Mifsud JJ, Rosati C, et al. Microsurgical selective posterior rhizotomy in the dorsal root entry zone for treatment of limb spasticity. Acta Neurochir Suppl (Wien).. 1987;39:99-102.
318. Mittal S, Farmer JP, Al Atassi B, et al. Impact of selective posterior rhizotomy on fine motor skills. Long-term results using a validated evaluative measure. Pediatr Neurosurg.. 2002;36(3):133-141.
319. Langerak NG, Lamberts RP, Fieggen AG, et al. Selective dorsal rhizotomy: long-term experience from Cape Town. Childs Nerv Syst.. 2007;23(9):1003-1006.
320. Langerak NG, Lamberts RP, Fieggen AG, et al. A prospective gait analysis study in patients with diplegic cerebral palsy 20 years after selective dorsal rhizotomy. J Neurosurg Pediatr.. 2008;1(3):180-186.
321. O'Brien DF, Park TS. A review of orthopedic surgeries after selective dorsal rhizotomy. Neurosurg Focus.. 2006;21(2):e2.
322. Steinbok P. Selection of treatment modalities in children with spastic cerebral palsy. Neurosurg Focus.. 2006;21(2):e4.
323. Farmer JP, Sabbagh AJ. Selective dorsal rhizotomies in the treatment of spasticity related to cerebral palsy. Childs Nerv Syst.. 2007;23(9):991-1002.
324. Abbott R. Complications with selective posterior rhizotomy. Pediatr Neurosurg.. 1992;18(1):43-47.
325. Kim DS, Choi JU, Yang KH, et al. Selective posterior rhizotomy in children with cerebral palsy: a 10-year experience. Childs Nerv Syst.. 2001;17(9):556-562.
326. Steinbok P, Schrag C. Complications after selective posterior rhizotomy for spasticity in children with cerebral palsy. Pediatr Neurosurg.. 1998;28(6):300-313.
327. Mittal S, Farmer JP, Poulin C, et al. Reliability of intraoperative electrophysiological monitoring in selective posterior rhizotomy. J Neurosurg.. 2001;95(1):67-75.
328. Sacco DJ, Tylkowski CM, Warf BC. Nonselective partial dorsal rhizotomy: a clinical experience with 1-year follow-up. Pediatr Neurosurg.. 2000;32(3):114-118.
329. Bertelli JA, Ghizoni MF, Michels A. Brachial plexus dorsal rhizotomy in the treatment of upper-limb spasticity. J Neurosurg.. 2000;93(1):26-32.
330. Turner MS. Dorsal rhizotomy. J Neurosurg.. 2005;103(1 suppl):1-2.
331. Crul BJ, Blok LM, van EJ, et al. The present role of percutaneous cervical cordotomy for the treatment of cancer pain. J Headache Pain.. 2005;6(1):24-29.
332. Gildenberg PL. Evolution of spinal cord surgery for pain. Clin Neurosurg.. 2006;53:11-17.
333. Hong D, Andre-Sandberg A. Punctate midline myelotomy: a minimally invasive procedure for the treatment of pain in inextirpable abdominal and pelvic cancer. J Pain Symptom Manage.. 2007;33(1):99-109.
334. Grabb PA, Doyle JS. The contemporary surgical management of spasticity in children. Phys Med Rehabil Clin N Am.. 2001;12(4):907-922, viii.
335. Keenan MA, Fuller DA, Whyte J, et al. The influence of dynamic polyelectromyography in formulating a surgical plan in treatment of spastic elbow flexion deformity. Arch Phys Med Rehabil.. 2003;84(2):291-296.
336. Mayer NH, Esquenazi A, Wannstedt G. Surgical planning for upper motor neuron dysfunction: the role of motor control evaluation. J Head Trauma Rehabil.. 1996;11(4):37-56.
337. Keenan M, Ahearn R, Lazarus M, et al. Selective release of spastic elbow flexors in the patient with brain injury. J Head Trauma Rehabil.. 1996;11(4):57-68.
338. Keenan MA. Surgical decision making for residual limb deformities following traumatic brain injury. Orthop Rev.. 1988;17(12):1185-1192.
339. Keenan MA, Ure K, Smith CW, et al. Hamstring release for knee flexion contracture in spastic adults. Clin Orthop Relat Res.. 1988;236:221-226.
340. Keenan MA, Lee GA, Tuckman AS, et al. Improving calf muscle strength in patients with spastic equinovarus deformity by transfer of the long toe flexors to the Os calcis. J Head Trauma Rehabil.. 1999;14(2):163-175.
341. Cipriano C, Keenan MA. Knee disarticulation and hip release for severe lower extremity contractures. Clin Orthop Relat Res.. 2007;462:150-155.
342. Gerszten PC, Albright AL, Johnstone GF. Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. J Neurosurg.. 1998;88(6):1009-1013.